Please use this identifier to cite or link to this item:

Full metadata record
DC FieldValueLanguage
dc.contributor.authorAroso, Ivo Manuel Ascensãopor
dc.contributor.authorSilva, João C.por
dc.contributor.authorMano, Franciscapor
dc.contributor.authorFerreira, Ana S. D.por
dc.contributor.authorDionísio, Madalenapor
dc.contributor.authorNogueira, Isabel Sápor
dc.contributor.authorBarreiros, Susanapor
dc.contributor.authorReis, R. L.por
dc.contributor.authorPaiva, Alexandrepor
dc.contributor.authorDuarte, Ana Rita C.por
dc.identifier.citationAroso I. M., Silva J. C., Mano F., Ferreira A. S., Dionísio M., Sá-Nogueira I., Barreiros S., Reis R. L., Paiva A., Duarte A. R. C. Dissolution enhancement of active pharmaceutical ingredients by therapeutic deep eutectic systems, European Journal of Pharmaceutics and Biopharmaceutics, Vol. 98, pp. 57-66, doi:10.1016/j.ejpb.2015.11.002, 2015por
dc.description.abstractA therapeutic deep eutectic system (THEDES) is here defined as a deep eutectic solvent (DES) having an active pharmaceutical ingredient (API) as one of the components. In this work, THEDESs are proposed as enhanced transporters and delivery vehicles for bioactive molecules. THEDESs based on choline chloride (ChCl) or menthol conjugated with three different APIs, namely acetylsalicylic acid (AA), benzoic acid (BA) and phenylacetic acid (PA), were synthesized and characterized for thermal behaviour, structural features, dissolution rate and antibacterial activity. Differential scanning calorimetry and polarized optical microscopy showed that ChCl:PA (1:1), ChCl:AA (1:1), menthol:AA (3:1), menthol:BA (3:1), menthol:PA (2:1) and menthol:PA (3:1) were liquid at room temperature. Dissolution studies in PBS led to increased dissolution rates for the APIs when in the form of THEDES, compared to the API alone. The increase in dissolution rate was particularly noticeable for menthol-based THEDES. Antibacterial activity was assessed using both Gram-positive and Gram-negative model organisms. The results show that all the THEDESs retain the antibacterial activity of the API. Overall, our results highlight the great potential of THEDES as dissolution enhancers in the development of novel and more effective drug delivery systems.por
dc.description.sponsorshipThe research leading to these results has received funding from the European Union's Seventh Framework Programme (FP7/2007-2013) under grant agreement no REGPOT-CT2012-316331-POLARIS and from Project "Novel smart and biomimetic materials for innovative regenerative medicine approaches (Ref.: RL1 - ABMR - NORTE-01-0124-FEDER-000016)" co-financed by North Portugal Regional Operational Programme (ON.2 - O Novo Norte), under the National Strategic Reference Framework (NSRF), through the European Regional Development Fund (ERDF). Funding was also provided by Fundacao para a Ciencia e a Tecnologia, through contracts LAQV, REQUIMTE: UID/QUI/50006/2013 and UCIBIO, REQUIMTE: UID/Multi/04378/2013.por
dc.subjectTherapeutic deep eutectic systemspor
dc.subjectDrug solubilitypor
dc.subjectGreen technologiespor
dc.subjectPharmaceutical and biomedical applicationspor
dc.titleDissolution enhancement of active pharmaceutical ingredients by therapeutic deep eutectic systemspor
oaire.citationTitleEuropean Journal of Pharmaceutics and Biopharmaceuticspor
dc.subject.wosScience & Technologypor
sdum.journalEuropean Journal of Pharmaceutics and Biopharmaceuticspor
Appears in Collections:3B’s - Artigos em revistas/Papers in scientific journals

Files in This Item:
File Description SizeFormat 
18636-1-s2.0-S093964111500452X-main (1).pdf
  Restricted access
2,54 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID